RESUMEN
Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disease areas including pulmonary fibrosis. Structural modifications of the known autotaxin inhibitor lead compound 1, to attenuate hERG inhibition, remove CYP3A4 time-dependent inhibition, and improve pharmacokinetic properties, led to the identification of clinical candidate GLPG1690 (11). Compound 11 was able to cause a sustained reduction of LPA levels in plasma in vivo and was shown to be efficacious in a bleomycin-induced pulmonary fibrosis model in mice and in reducing extracellular matrix deposition in the lung while also reducing LPA 18:2 content in bronchoalveolar lavage fluid. Compound 11 is currently being evaluated in an exploratory phase 2a study in idiopathic pulmonary fibrosis patients.
Asunto(s)
Fibrosis Pulmonar Idiopática/tratamiento farmacológico , Imidazoles/uso terapéutico , Hidrolasas Diéster Fosfóricas/efectos de los fármacos , Pirimidinas/uso terapéutico , Animales , Humanos , Imidazoles/farmacología , Ratones , Ratones Noqueados , Hidrolasas Diéster Fosfóricas/genética , Pirimidinas/farmacología , RatasRESUMEN
The aim of this study was to investigate lipophilicity and cellular accumulation of rationally designed azithromycin and clarithromycin derivatives at the molecular level. The effect of substitution site and substituent properties on a global physico-chemical profile and cellular accumulation of investigated compounds was studied using calculated structural parameters as well as experimentally determined lipophilicity. In silico models based on the 3D structure of molecules were generated to investigate conformational effect on studied properties and to enable prediction of lipophilicity and cellular accumulation for this class of molecules based on non-empirical parameters. The applicability of developed models was explored on a validation and test sets and compared with previously developed empirical models.
Asunto(s)
Antibacterianos/química , Antibacterianos/farmacocinética , Azitromicina/análogos & derivados , Azitromicina/farmacocinética , Claritromicina/análogos & derivados , Claritromicina/farmacocinética , Humanos , Modelos Biológicos , Modelos Químicos , Conformación Molecular , Simulación de Dinámica MolecularRESUMEN
Malondialdehyde (MDA) is stabile product of lipid peroxidation (LPO), and therefore MDA is frequently used as a biomarker of LPO. To determine MDA level in various biological samples (human plasma, fish liver tissue and cells in culture), we used an HPLC method with fluorescent detection based on 2-thiobarbituric acid (TBA) assay. The method was validated by the use of spiked pooled plasma samples. In tested concentration range (0.15-3.0 µmol/L) the method was linear (R(2) = 0.9963), the between-day variability (coefficient of variations, CVs) was between 4.7 and 7.6%, the within-day variability CVs was between 2.6 and 6.4% and recovery was between 91.2 and 107.6%. The level of MDA in human plasma (healthy male, non-smokers, 46.3 ± 4.7 years; N = 38) was 2.2 ± 1.4 µmol/L; that in liver tissue of common carp (Cyprinus carpio; N = 12) was 0.02 ± 0.004 µmol/g tissue, and in cultured cells (human laryngeal carcinoma cells; N = 10) it was 0.18 ± 0.02 nmol/mg proteins. The HPLC-FL method is rapid, accurate and reliable to follow the extent of LPO in various biological samples, particularly in samples in which a low level of MDA is expected, such as cells in culture. Owing to the rapid analytical process and run time, it can be used for routine analysis of MDA in clinical laboratory.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Malondialdehído/análisis , Espectrometría de Fluorescencia/métodos , Animales , Línea Celular Tumoral , Humanos , Modelos Lineales , Hígado/química , Malondialdehído/química , Malondialdehído/metabolismo , Reproducibilidad de los Resultados , Tiobarbitúricos/química , Tiobarbitúricos/metabolismoRESUMEN
The purpose of this study was to evaluate the impact of structural modifications on the 15-membered macrolactone ring and/or substituents on the in vitro ADME properties and in vivo pharmacokinetic (PK) profile for selected derivatives in rodents in comparison to azithromycin. Azithromycin and seven selected 15-membered macrolide derivatives, modified either by removal of the sugar moieties, replacement of the amine with a lactam, or addition of lipophilic substituents, were screened in several in vitro ADME assays and in vivo PK studies in rodents. In vitro ADME profiling included assessment of passive permeability and P-gp substrate, metabolic stability in liver microsomes and hepatocytes, as well as CYP direct inhibition measurements. In vivo PK studies were performed in rats (Sprague-Dawley), mice (Balb/c), and P-gp wild-type and deficient mice (CF-1™). Different structural modifications on the azithromycin scaffold resulted in substantial changes in disposition kinetics and oral bioavailability in both rodent species. However, these differences in vivo cannot be predicted based on in vitro results since most of these molecules are classified in the same category. Therefore, in the case of 15-membered ring macrolides, the in vitro ADME screens presented here seem to have low predictive value for in vivo prediction, making their use as routine in vitro screens prior to PK assessments questionable.
Asunto(s)
Antibacterianos/farmacocinética , Azitromicina/farmacocinética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/fisiología , Administración Oral , Animales , Antibacterianos/administración & dosificación , Antibacterianos/química , Azitromicina/administración & dosificación , Azitromicina/química , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Estabilidad de Medicamentos , Inyecciones Intravenosas , Masculino , Ratones , Ratones Endogámicos BALB C , Ratas , Ratas Sprague-Dawley , Distribución TisularRESUMEN
A new concept in design of safe glucocorticoid therapy was introduced by conjugating potent glucocorticoid steroids with macrolides (macrolactonolides). These compounds were synthesized from various steroid 17ß-carboxylic acids and 9a-N-(3-aminoalkyl) derivatives of 9-deokso-9a-aza-9a-homoeritromicin A and 3-descladinosyl-9-deokso-9a-aza-9a-homoeritromicin A using stable alkyl chain. Combining property of macrolides to preferentially accumulate in immune cells, especially in phagocyte cells, with anti-inflammatory activity of classic steroids, we designed molecules which showed good anti-inflammatory activity in ovalbumin (OVA) induced asthma in rats. The synthesis, in vitro and in vivo anti-inflammatory activity of this novel class of compounds are described.
Asunto(s)
Antiinflamatorios/química , Antiinflamatorios/uso terapéutico , Asma/tratamiento farmacológico , Macrólidos/química , Macrólidos/uso terapéutico , Esteroides/química , Esteroides/uso terapéutico , Animales , Antiinflamatorios/farmacocinética , Asma/inducido químicamente , Ácidos Carboxílicos , Línea Celular , Diseño de Fármacos , Glucocorticoides/química , Glucocorticoides/farmacocinética , Glucocorticoides/uso terapéutico , Macrólidos/farmacocinética , Masculino , Ratones , Ratones Endogámicos BALB C , Ratas , Ratas Endogámicas BN , Esteroides/farmacocinéticaRESUMEN
The aim of this study was to compare the roles of gastrointestinal absorption and hepatic extraction as barriers to oral bioavailability for macrolide antibiotics erythromycin, clarithromycin, roxithromycin and telithromycin. In this study, the in vitro metabolic stability in rat liver microsomes and hepatocytes, as well as the in vivo pharmacokinetics in rats were determined following intravenous, intraportal, oral and intraduodenal routes of administration. Pharmacokinetic parameters were calculated for each compound for each route of administration. In vitro metabolic stability studies point to low intrinsic clearance of the tested macrolides in both microsomes (<1 mL/min/g) and hepatocytes (<1 mL/min/g), indicating good stability. The oral bioavailability in rat was low to moderate (14, 36, 36 and 25% for erythromycin, clarithromycin, roxithromycin and telithromycin, respectively). Upon intraduodenal dosing, the bioavailability increased by 1.3-3-fold, the highest increase being with roxithromycin, suggesting some loss due to gastric instability. Following portal vein administration, no hepatic first pass effect was observed with roxithromycin, less than 10% with telithromycin, and ca. 20 and 25% for clarithromycin and erythromycin. Our data showed that the tested macrolides display good in vitro metabolic stability, as was confirmed in vivo where a low hepatic first pass effect was observed. The limited oral bioavailability is likely due to poor oral absorption and/or intestinal first pass metabolism.
Asunto(s)
Antibacterianos/farmacocinética , Macrólidos/farmacocinética , Animales , Antibacterianos/administración & dosificación , Disponibilidad Biológica , Claritromicina/farmacocinética , Eritromicina/farmacocinética , Hepatocitos/metabolismo , Cetólidos/farmacocinética , Macrólidos/administración & dosificación , Masculino , Microsomas Hepáticos/metabolismo , Ratas , Ratas Sprague-Dawley , Roxitromicina/farmacocinéticaRESUMEN
Some macrolide antibiotics were reported to inhibit interleukin-6 (IL6) and prostaglandin-E2 (PGE(2)) production by bacterial lipopolysaccharide (LPS) stimulated J774A.1 cells. Macrolides are also known to accumulate in cells and some were proven inducers of phospholipidosis. In the present study, with a set of 18 mainly 14- and 15-membered macrolides, we have investigated whether these macrolide induced phenomena in J774A.1 cells are connected. In LPS-stimulated J774A.1 cells, the extent of inhibition of proinflammatory markers (IL6 and PGE(2)) by macrolides significantly correlated with their extent of accumulation in cells, as well as with the induction of phospholipidosis, and cytotoxic effects in prolonged culture (with correlation coefficients (R) ranging from 0.78 to 0.93). The effects observed were related to macrolide binding to phospholipids (CHI IAM), number of positively charged centres, and were inversely proportional to the number of hydrogen bond donors. Similar interdependence of effects was obtained with chloroquine and amiodarone, whereas for dexamethasone and indomethacin these effects were not linked. The observed macrolide induced phenomena in J774A.1 cells were reversible and elimination of the macrolides from the culture media prevented phospholipidosis and the development of cytotoxicity in long-term cultures. Based on comparison with known clinical data, we conclude that LPS-stimulated J774A.1 cells in presented experimental setup are not a representative cellular model for the evaluation of macrolide anti-inflammatory potential in clinical trials. Nevertheless, our study shows that, at least in in vitro models, binding to biological membranes may be the crucial factor of macrolide mechanism of action.
Asunto(s)
Antibacterianos/inmunología , Antiinflamatorios/inmunología , Macrólidos/inmunología , Fosfolípidos/metabolismo , Animales , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Antiinflamatorios/farmacocinética , Antiinflamatorios/farmacología , Sitios de Unión , Línea Celular , Permeabilidad de la Membrana Celular , Supervivencia Celular/efectos de los fármacos , Dinoprostona/inmunología , Interleucina-6/inmunología , Lipopolisacáridos/inmunología , Macrólidos/farmacocinética , Macrólidos/farmacología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/metabolismo , RatonesRESUMEN
Macrolides with 14- and 15-membered ring are characterized by high and extensive tissue distribution, as well as good cellular accumulation and retention. Since macrolide structures do not fit the Lipinski rule of five, macrolide pharmacokinetic properties cannot be successfully predicted by common models based on data for small molecules. Here we describe the development of the first models for macrolide cellular pharmacokinetics. By comparison of cellular accumulation and retention in six human primary cell cultures of leukocytic and lung origin, as well as in lung carcinoma cell line NCI-H292, this cell line was found to be an adequate representative cell type for modeling macrolide cellular pharmacokinetics. Accumulation and retention in the NCI-H292 cells, as well as various physicochemical properties, were determined for a set of 48 rationally designed basic macrolide compounds. Classification models for predicting macrolide cellular accumulation and retention were developed using relatively easily determined and conceptually simple descriptors: experimentally determined physicochemical parameters ChromlogD and CHI IAM, as well as a calculated number of positively charged atoms (POS). The models were further tested and improved by addition of 37 structurally diverse macrolide molecules.
Asunto(s)
Macrólidos/farmacocinética , Modelos Biológicos , Línea Celular Tumoral , Fenómenos Químicos , Humanos , Leucocitos/citología , Leucocitos/metabolismo , Pulmón/citología , Pulmón/metabolismo , Neoplasias Pulmonares , Macrólidos/química , Cultivo Primario de Células , Mucosa Respiratoria/citología , Mucosa Respiratoria/metabolismo , Relación Estructura-ActividadRESUMEN
The stability in aqueous solution of five classes of coumarin dimers (I-V, compounds 1-29) was studied by HPLC-MS/MS at various pH values. The relationship between chemical structure and stability is discussed. It was found that dimeric compounds with strong electron withdrawing groups (EWGs) on the α-carbon to the bridging C-atom are stable at all pH values, whereas other derivatives undergo retro-Michael addition at rates which are also affected by the substituents on the aromatic rings. In some cases formation of stable isomers or oxidation products was observed. In order to evaluate their developability and potential for progression to in vivo studies, representative compounds were tested in an in vitro microsomal stability assay.